Oslo, Norway, 30 March 2023 - Photocure ASA (the "Company") (OSE: PHO) has
granted share options to employees.
A total of 33,900 share options, equal to 0.12% of total shares issued in the
Company, were granted at an exercise price at NOK 85.78. The exercise price is
equal to the weighted average share price 30 trading days before day of grant
with an additional premium of 10% on top of the calculated average price.
All of the options have been granted to employees. The options are granted in
accordance with Photocure's long term incentive program.
Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.